TABLE 1

Patient Characteristics and Neuroimaging Findings

Patient	Sex	Age at Dx	MGMT promoter methylation	IDH mutation	Dx	EOR	MTV BL (mL)	MTV FU (mL)	TBR_mean BL	TBR_mean FU	TBR_max BL	TBR_max FU	MRI res	PFS (mo)	OS (mo)
1	M	66	meth	wt	GBM	B	42.8	20.8	2.3	2.2	3.1	2,5	PD	16	29
2	M	47	meth	wt	GBM	B	10.7	20.2	2.0	2.2	2.0	2.6	SD	16	21
3	M	62	meth	wt	GBM	CR	5.2	4.3	1.9	1.9	1.9	1.9	SD	11	31
4	M	76	meth	wt	GBM	B	95.5	n.a.	2.1	n.a.	2.8	n.a.	PD	3	5
5	M	69	not meth	wt	GBM	CR	3.4	4.1	1.8	1.8	1.8	1.8	SD	9	34
6	M	69	meth	wt	GBM	B	37.8	n.a.	1.9	n.a.	2.3	n.a.	SD	4	5
7	M	44	not meth	wt	GBM	PR	18.4	14.2	1.9	1.8	1.9	1.8	PD	11	17
8	F	50	meth	wt	GBM	B	8.4	15.8	1.9	1.9	2.4	2.6	SD	5	12
9	F	49	not meth	wt	GBM	PR	26.8	53.7	1.9	1.9	2.0	2.1	PD	11	12
10	F	58	meth	wt	GBM	B	4.3	4.3	2.0	1.9	2.0	1.9	SD	54^*	54^*
11	M	30	not meth	wt	GBM	PR	17.8	18.9	2.1	2.2	2.8	3.1	SD	8	14
12	M	54	not meth	wt	GBM	PR	60.7	101.0	1.8	2.1	2.0	2.3	PD	8	10
13	F	66	not meth	wt	GBM	B	103.2	137.1	2.6	2.2	4.4	3.2	PD	10	11
14	M	44	meth	mut	GBM	B	13.8	8.4	1.8	1.9	2.0	2.1	PD	15	54^*
15	M	58	meth	wt	GBM	CR	43.6	82.1	1.9	2.0	2.1	2.3	SD	5	11
16	F	61	not meth	NOS	GBM	CR	44.1	44.5	2.3	2.4	2.8	3.2	PD	8	50
17	M	61	not meth	wt	GBM	B	29.7	38.3	2.2	2.2	2.5	3.1	PD	4	5
18	F	26	meth	wt	GBM	CR	2.4	0.7	1.9	1.8	1.9	1.8	SD	37	47^*
19	F	51	not meth	wt	GBM	CR	1.8	4.5	1.8	1.8	1.8	1.8	PD	12	22
20	F	50	not meth	wt	GBM	CR	14.2	10.7	1.8	1,8	1.8	1.8	n.a.	10	10
21	M	59	not meth	NOS	GBM	PR	10.8	24.9	2.0	1.9	2.1	2.3	SD	7	10
22	M	39	not meth	wt	GBM	B	3.2	11.5	2.0	2.2	2.0	2.8	PD	5	10
23	F	54	meth	wt	AA	B	0.0	0.0	1.7	1.3.	1.7	1.3.	SD	30	31^*
24	F	32	meth	mut	GBM	PR	3.6	14.9	2.2	1.8	2.2	1.8	PD	12	24
25	F	20	not meth	wt	H3K27 M	PR	1.4	0.6	1.8	1.7	1.8	1.7	PD	18	31
26	M	66	meth	wt	AA	B	0.6	3.2	1.7	1.8	1.7	1.8	SD	11	16
27	M	46	not meth	wt	GBM	CR	12.7	14.7	1.9	2.0	1.9	2.1	SD	9	16
28	F	66	meth	wt	GBM	CR	13.5	9.3	1.8	1.8	1.9	1.9	PD	8	17
29	M	48	meth	mut	GBM	CR	14.6	5.6	1.9	1.8	2.1	1.8	PD	24^*	24^*
30	F	49	not meth	wt	GBM	CR	7.2	14.9	1.8	2.0	1.8	2.3	PD	11	22
31	M	38	not meth	wt	GBM	PR	75.5	40.2	1.8	1.9	2.3	2.5	SD	6	12
32	F	52	not meth	wt	GBM	PR	48.9	48.5	2.5	2.3	3.5	3.0	PD	4	13
33	M	46	meth	wt	GBM	B	2.6	n.a.	1.8	n.a.	1.8	n.a.	SD	4^*	8
34	F	68	not meth	wt	GBM	PR	41.6	26.3	2.0	1.8	2.0	1.8	PD	7	15
35	M	79	not meth	wt	GBM	B	58.0	59.0	2.3	2.1	3.2	2.4	PD	6	6
36	F	43	not meth	wt	GBM	B	67.0	54.0	2.1	2.0	3.3	2.6	PD	7	14^*
37	M	58	not meth	wt	GBM	B	6.0	7.0	1.9	2.0	1.9	2.0	PD	9^*	12
38	F	54	not meth	wt	GBM	B	2.1	2.6	1.7	1.7	1.7	1.7	SD	9	9^*
39	F	62	not meth	wt	GBM	PR	69.2	102.6	2.1	2.3	2.4	3.3	SD	7	9
40	M	42	n.a.	wt	A	B	10.8	15.4	2.1	2.1	2.3	2.2	PD	6	11^*
41	F	49	not meth	wt	GBM	PR	15.6	6.9	1.9	1.8	1.9	1.8	PD	12	14

↵* Censored.
A = astrocytoma (WHO grade II); AA = anaplastic astrocytoma; B = biopsy; BL = baseline; CR = complete resection; EOR = extent of resection; F = female; FU = follow-up; GBM = glioblastoma; H3K27 = H3K27-mutant diffuse midline glioma; M = male; meth = MGMT promoter methylated; MGMT = O⁶-methylguanine-DNA methyltransferase; Dx = diagnosis; MTV = metabolic tumor volume; mut = mutant; n.a. = not available; NOS = not otherwise specified; PD = “progressive disease” according to RANO criteria; PFS = progression-free survival; PR = partial resection/“partial response” according to RANO criteria; res = response; SD = “stable disease” according to RANO criteria; TBR_max, TBR_mean = maximum and mean tumor-to-brain ratio; wt = wildtype.